Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Geron Corp GERN

Alternate Symbol(s):  GERNW

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the... see more

NDAQ:GERN - Post Discussion

Geron Corp > Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is '
View:
Post by whytestocks on Apr 11, 2024 2:00pm

Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is '

News; $GERN Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me' | BenzingaOn CNBC’s "Mad Money Lightning Round," Jim Cramer said "no" to MarineMax Inc (NYSE: HZO). "It's just too risky...GERN - Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me' | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities